1-6 of 126 Activities
In the third activity of this CME Outfitters Q&A series, expert faculty will answer questions about improving health equity in gastrointestinal care. The focus will be on understanding upstream, midstream, and downstream drivers of health inequities, such as socioeconomic status, immigration status, and lack of social support. Learners will gain actionable strategies, including utilizing case managers, interpreter services, culturally aligned dieticians, and community support workers to address social drivers of health. These strategies aim to improve diagnosis, treatment, and outcomes for underserved populations, fostering equitable gastrointestinal care delivery.
Neilanjan Nandi, FACG, AGAF, FACP, is Associate Professor of Clinical Medicine at Penn Presbyterian Medical Center at the University of Pennsylvania. Dr. Nandi’s practice focuses on the management of inflammatory bowel disease (IBD) (e.g., Crohn’s disease, ulcerative colitis) and recurrent Clostridium difficile (C. difficile) infection via fecal microbiota transplantation (FMT). Dr. Nandi serves on the executive council of the Philadelphia Crohn’s & Colitis Foundation (CCF) and on the medical advisory board of the United Ostomy Associates of America (UOAA), coordinates outreach on the American College of Gastroenterology Patient Care Committee, and is a founding board member of the South Asian IBD Alliance (SAIA). He also regularly peer reviews research publications and serves on the social media editorial board for the premier journals Inflammatory Bowel Diseases and Crohn’s & Colitis 360. His research has focused on studying conditions co-morbid to IBD quality of care, namely the diagnosis and management of refractory C. difficile infection and the application of FMT in C. difficile; also, characterizing the management and consequences of iron deficiency anemia and non-alcoholic fatty liver disease in patients with IBD. Dr. Nandi has authored numerous book chapters on the diagnosis and management of various viral, parasitic, mycobacterial, and bacterial infections of the gastrointestinal (GI) tract.
Dr. Nandi’s fervor for clinical education has been recognized with multiple teaching awards. He was honored as the 2019 Physician Hero by the Philadelphia/Delaware Valley Crohn’s and Colitis Foundation at their annual Take Steps for Crohn’s & Colitis event, and wields digital and social media platforms to amplify education, outreach, and advocacy in IBD to clinicians and patients. He was also awarded the Philadelphia CCF’s Chairman’s Citation in 2022. He is the regular host of the academic podcast GI Insights: IBD Crosstalk, which features high-yield, evidence-based medicine discussions with guests from different interdisciplinary fields critical to providing comprehensive IBD care. Dr. Nandi’s passions include fitness, cooking, virtual reality gaming, reading, and dancing. Follow him on social @fitwitmd.
In the first activity of this CME Outfitters BriefCase series, expert faculty will discuss actionable strategies to enhance health equity in the management of cardiovascular disorders. The focus will be on identifying and addressing social drivers of health (SDoH) that contribute to disparities, integrating holistic treatment approaches, and employing team-based strategies to ensure equitable care. Learners will gain tools to improve the diagnosis, treatment, and long-term management of hypertension and other cardiovascular conditions, particularly in high-risk, underserved populations.
In the first activity of this CME Outfitters podcast series on gynecologic cancers, expert faculty will present and discuss the very latest research on maintenance treatment of EC and how to assess its value for newly diagnosed patients and those with recurrent EC.
Richard T. Penson, MD, MRCP, is a Medical Oncologist at Massachusetts General Hospital, and Associate Professor of Medicine at Harvard Medical School. A key opinion leader, Dr. Penson was a longstanding member of the Gynecologic Oncology Group Ovarian and Quality of Life Committees and now serves on the Foundation’s Investigator Council. He is the national Principal Investigator (PI) of the olaparib registration trial (SOLO-2) and the international PI of SOLO3, and the OVAL trial. He has taught on Harvard’s Practice of Medicine Course, the Bigelow General Medical Service at Massachusetts General Hospital, and is one of the Chairs of the Institutional Review Board of Dana-Farber Harvard Cancer Center.
In this CMEO “BriefCase,” expert faculty will walk learners through a real-world case and review unmet needs that persist for patients and caregivers. By identifying the impact of DEEs on patients and using real-world evidence to individualize treatment plans for patients with LGS, a collaborative and multidisciplinary approach to therapeutic decision-making can be realized.
Dr. Dixon-Salazar is a neuroscientist, geneticist, and patient advocate. Her desire to get her PhD was inspired by her daughter who developed Lennox-Gastaut Syndrome (LGS) at the age of 2. She completed her PhD and postdoctoral work at UC, San Diego, where she studied the mechanisms of brain development and synaptic plasticity, identified genetic causes of rare disorders in children, and researched precision therapeutics in stem cell and animal models of pediatric disease. During her research tenure, and after 16 years of watching daily, unrelenting seizures in her child, she uncovered the driver of her daughter’s illness and identified a novel precision therapy that improved her child’s life.
Dr. Dixon-Salazar left academia after 15 years in the lab with a drive to decrease the amount of time it would take for patients to benefit from lab discoveries in epilepsy precision medicine. She worked as Associate Research Director at CURE Epilepsy helping to move funding forward for novel translational research in genomic medicine for patients with severe forms of pediatric-onset epilepsy. She then transitioned to the Director of Research and Strategy at the Lennox-Gastaut Syndrome (LGS) Foundation where she worked directly with patients to access precision therapies and partnered with researchers, clinicians, regulators, policymakers, therapy developers, and other advocacy groups to build a sustainable precision medicine infrastructure for all patients with epilepsy. Currently, Dr. Dixon- Salazar serves as the Executive Director of the LGS Foundation, where the mission is to improve the lives of individuals impacted by LGS through advancing research, awareness, education, and family support
This CMEO “Snack” will offer clinicians the chance to learn from expert faculty, informed upon by real-world unmet needs identified among HCPs, patients, and caregivers, including topics such as identifying the impact of DEEEs on patients, incorporating the latest clinical trial data and real-world evidence to individualize treatment plans for patients with LGS, and integrating a collaborative approach to therapeutic decision-making..
In the third activity of this CME Outfitters BriefCase series, expert faculty will explore strategies to improve health equity in gastrointestinal care. The focus will be on understanding upstream, midstream, and downstream drivers of health inequities, such as socioeconomic status, immigration status, and lack of social support. Learners will gain actionable strategies, including utilizing case managers, interpreter services, culturally aligned dieticians, and community support workers to address social drivers of health. These strategies aim to improve diagnosis, treatment, and outcomes for underserved populations, fostering equitable gastrointestinal care delivery.
Neilanjan Nandi, FACG, AGAF, FACP, is Associate Professor of Clinical Medicine at Penn Presbyterian Medical Center at the University of Pennsylvania. Dr. Nandi’s practice focuses on the management of inflammatory bowel disease (IBD) (e.g., Crohn’s disease, ulcerative colitis) and recurrent Clostridium difficile (C. difficile) infection via fecal microbiota transplantation (FMT). Dr. Nandi serves on the executive council of the Philadelphia Crohn’s & Colitis Foundation (CCF) and on the medical advisory board of the United Ostomy Associates of America (UOAA), coordinates outreach on the American College of Gastroenterology Patient Care Committee, and is a founding board member of the South Asian IBD Alliance (SAIA). He also regularly peer reviews research publications and serves on the social media editorial board for the premier journals Inflammatory Bowel Diseases and Crohn’s & Colitis 360. His research has focused on studying conditions co-morbid to IBD quality of care, namely the diagnosis and management of refractory C. difficile infection and the application of FMT in C. difficile; also, characterizing the management and consequences of iron deficiency anemia and non-alcoholic fatty liver disease in patients with IBD. Dr. Nandi has authored numerous book chapters on the diagnosis and management of various viral, parasitic, mycobacterial, and bacterial infections of the gastrointestinal (GI) tract.
Dr. Nandi’s fervor for clinical education has been recognized with multiple teaching awards. He was honored as the 2019 Physician Hero by the Philadelphia/Delaware Valley Crohn’s and Colitis Foundation at their annual Take Steps for Crohn’s & Colitis event, and wields digital and social media platforms to amplify education, outreach, and advocacy in IBD to clinicians and patients. He was also awarded the Philadelphia CCF’s Chairman’s Citation in 2022. He is the regular host of the academic podcast GI Insights: IBD Crosstalk, which features high-yield, evidence-based medicine discussions with guests from different interdisciplinary fields critical to providing comprehensive IBD care. Dr. Nandi’s passions include fitness, cooking, virtual reality gaming, reading, and dancing. Follow him on social @fitwitmd.